BBNX vs BIIB · rev $100.3M vs P/E 21, rev $9.89B
Beta Bionics, Inc. Common Stock (BBNX) versus Biogen Inc (BIIB) — a side-by-side from cached financials, not a winner call.
Beta Bionics, Inc. Common Stock (BBNX) is a medical devices company listed on NASDAQ.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Latest reported BBNX revenue for 2025-12-31 was $100.3M. Net income was -$73.2M. Revenue was up 53.9% from 2024-12-31 to 2025-12-31. BBNX currently screens at market cap $640.8M.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
BBNX currently screens at market cap $640.8M. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Not investment advice. Open the BBNX and BIIB stock pages for the full models.
Not investment advice.